The influence of frusemide formulation on diuretic effect and efficiency

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 361-366

  Wakelkamp, Monique ^a   Blechert, Åsa ^b   Eriksson, Maria ^c   Gjellan, Kirsti ^d   Graffner, Christina ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Medical Department   (Norway)

^c Prod Devmt Prod Sourcing/Mgmt   (Norway)

^d ASTRAZENECA R AND D   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Efficiency; Extended release; Frusemide; Pharmacodynamics

Indexed keywords

FUROSEMIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINE VOLUME;

ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIURESIS; DIURETICS; DOUBLE-BLIND METHOD; FUROSEMIDE; HUMANS; MALE;

EID: 0032818302     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00015.x     Document Type: Article

References (17)

1. Banerjee PS, Robinson JR. Novel drug delivery systems: an overview of their impact on clinical pharmacokinetic studies. Clin Pharmacokinet 1991; 20: 1-14.
2. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22: 69-74.
3. Alván G, Helleday L, Lindholm A, Sanz E, Villén T. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide. Br J Clin Pharmacol 1990; 29: 215-219.
4. Alván G, Paintaud G, Eckernäs S-Å, Grahnén A. Discrepancy between bioavailabillty as estimated from urinary recovery of frusemide and total diuretic effect. Br J Clin Pharmacol 1992; 34: 47-52.
5. van Meyel JJ, Smits P, Russel FG, Gerlag PG, Tan Y, Gribnau FW. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther 1992; 51: 440-444.
6. Paintaud G, Alván G, Eckernäs S-Å, Wakelkamp M, Grahnén A. The influence of food intake on the effect of two controlled release formulations of furosemide. Biopharm Drug Dispos 1995; 16: 221-232.
7. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficiency of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376-382.
8. Wakelkamp M, Alván G, Paintaud G. Natriuretic efficiency of frusemide as a consequence of drug input rate. Br J Clin Pharmacol 1997; 43: 481-491.
9. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985; 233: 447-453.
10. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide I. Effects of salt intake and renal compensation. J Lab Clin Med 1983; 102: 450-458.
11. Ferguson JA, Sundblad KJ, Becker PK, Gorski JC, Rudy DW, Brater DC. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997; 62: 203-208.
12. Wakelkamp M, Alván G, Paintaud G. The time of maximum diuretic effect for model selection in pharmacokinetic-pharmacodynamic analysis of furosemide. Br J Clin Pharmacol 1998; 45: 63-70.
13. Murray MD, Haag KM, Black PK, Hall SD, Brater DC. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997; 17: 98-106.
14. Waller ES, Crismon ML, Smith RV, Bauza MT, Doluisio JT. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. Biopharm Drug Dispos 1988; 9: 211-218.
15. McNamara PJ, Foster TS, Digenis GA, et al. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. Pharm Res 1987; 4: 151-153.
16. Kingsford M, Eggers NJ, Soteros G, Maling TJB, Shirkey RJ. An in-vivo-in-vitro correlation for the biovailability of frusemide tablets. J Pharm Pharmacol 1984; 36: 536-538.
17. Grahnén A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 1984; 27: 595-602.